Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
BMS-986179
i
Other names:
BMS-986179, BMS 986179, BMS986179
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
BMS
Drug class:
CD73 inhibitor
Related drugs:
‹
MEDI9447 (6)
TJD5 (3)
INT-1B3 (1)
ABSK051 (0)
BP1200 (0)
HB0045 (0)
HLX23 (0)
INCA00186 (0)
IPH5301 (0)
NZV930 (0)
ORIC-533 (0)
PM1015 (0)
S95024 (0)
AGEN1423 (0)
AK119 (0)
CPI-006 (0)
AB680 (0)
MEDI9447 (6)
TJD5 (3)
INT-1B3 (1)
ABSK051 (0)
BP1200 (0)
HB0045 (0)
HLX23 (0)
INCA00186 (0)
IPH5301 (0)
NZV930 (0)
ORIC-533 (0)
PM1015 (0)
S95024 (0)
AGEN1423 (0)
AK119 (0)
CPI-006 (0)
AB680 (0)
›
Associations
News
Trials
Filter by
Latest
over3years
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov)
P1/2, N=268, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Nov 2020 --> Feb 2023
over 3 years ago
Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
CD73 (5'-Nucleotidase Ecto)
|
CD73 expression
|
Opdivo (nivolumab) • BMS-986179
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login